These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431 [TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population. Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262 [TBL] [Abstract][Full Text] [Related]
6. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Slats D; Claassen JA; Spies PE; Borm G; Besse KT; van Aalst W; Tseng J; Sjögren MJ; Olde Rikkert MG; Verbeek MM Neurobiol Aging; 2012 Apr; 33(4):831.e1-9. PubMed ID: 21880396 [TBL] [Abstract][Full Text] [Related]
7. Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid. Schipke CG; Prokop S; Heppner FL; Heuser I; Peters O Dement Geriatr Cogn Disord; 2011; 31(2):139-45. PubMed ID: 21304219 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971 [TBL] [Abstract][Full Text] [Related]
10. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147 [TBL] [Abstract][Full Text] [Related]
11. Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40). Vanderstichele H; Demeyer L; Janelidze S; Coart E; Stoops E; Mauroo K; Herbst V; François C; Hansson O Alzheimers Res Ther; 2017 Jun; 9(1):40. PubMed ID: 28587660 [TBL] [Abstract][Full Text] [Related]
12. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282 [TBL] [Abstract][Full Text] [Related]
13. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Vanderstichele H; Bibl M; Engelborghs S; Le Bastard N; Lewczuk P; Molinuevo JL; Parnetti L; Perret-Liaudet A; Shaw LM; Teunissen C; Wouters D; Blennow K Alzheimers Dement; 2012 Jan; 8(1):65-73. PubMed ID: 22047631 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting. Gervaise-Henry C; Watfa G; Albuisson E; Kolodziej A; Dousset B; Olivier JL; Jonveaux TR; Malaplate-Armand C J Alzheimers Dis; 2017; 57(2):437-445. PubMed ID: 28269771 [TBL] [Abstract][Full Text] [Related]
15. [A new approach to the Alzheimer's disease diagnosis with biomarkers: description of the AD-CSF-Index]. Molinuevo JL; Gispert JD; Pujol J; Rojas S; Lladó A; Balasa M; Antonell A; Sánchez-Valle R; Rami L Rev Neurol; 2012 May; 54(9):513-22. PubMed ID: 22532214 [TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer's disease patients. Kandimalla RJ; S P; Bk B; Wani WY; Sharma DR; Grover VK; Bhardwaj N; Jain K; Gill KD Neurosci Lett; 2011 Jan; 487(2):134-8. PubMed ID: 20599474 [TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
19. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages. Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118 [TBL] [Abstract][Full Text] [Related]
20. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Verwey NA; van der Flier WM; Blennow K; Clark C; Sokolow S; De Deyn PP; Galasko D; Hampel H; Hartmann T; Kapaki E; Lannfelt L; Mehta PD; Parnetti L; Petzold A; Pirttila T; Saleh L; Skinningsrud A; Swieten JC; Verbeek MM; Wiltfang J; Younkin S; Scheltens P; Blankenstein MA Ann Clin Biochem; 2009 May; 46(Pt 3):235-40. PubMed ID: 19342441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]